Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF

Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF hamster model at the Keystone conference

Combining three independent pathological stressors induces a heart

François Briand en LinkedIn: #nash #fibrosis #obesity

Pathophysiological mechanisms of heart failure with preserved

News - Physiogenex

Heart failure in type 2 diabetes: current perspectives on

Frontiers Microvascular Dysfunction in Heart Failure With

HFpEF Is the Substrate for Stroke in Obesity and Diabetes

Immunometabolic mechanisms of heart failure with preserved

Functional and Metabolic Imaging in Heart Failure with Preserved

HFpEF: Should We Consider Diabetic Patients Separately?: The

Physiogenex and Cardiomedex to present a new diabetic NASH HFpEF

Liraglutide shows superior cardiometabolic benefits than

François Briand on LinkedIn: Preclinical CRO for metabolic

Physiogenex on LinkedIn: #nash #obesity #preclinicalresearch

Diabetes & Obesity in HFpEF: New targets in heart failure